Clinical and pharmacological approaches to present-day influenza anti-viral therapy

Abstract

Up to 646,000 people worldwide die from seasonal influenza-related respiratory illnesses each year. According to new estimates by WHO, the prevalence of three strains of the influenza virus is expected in the 2017-2018 epidemic season: Influenza A (H1N1), A (H3N2), and influenza B viruses. In this regard, the issue of prescribing rational etiotropic antiviral therapy becomes particularly topical. Neuraminidase inhibitors are currently the first line drugs that are recommended by WHO for the treatment and prevention of influenza.

Keywords

• influenza
• neuraminidase inhibitors
• oseltamivir
• resistance